Not applicableActive Not RecruitingNCT02185560
What this trial is testing
Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
Who this might be right for
Thyroid Carcinoma
Bayer 453